Celltrion and WuXi XDC Partner to Advance ADC Development and Manufacturing

WuXi XDC, a global Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in bioconjugates, and Celltrion, a biopharmaceutical company focused on innovative therapeutics, have entered into a strategic partnership. The Memorandum of Understanding (MOU) outlines comprehensive and integrated services for the development and manufacturing of bioconjugates, particularly antibody-drug conjugates (ADCs).

Related article: Reviewing the Market Trends in the Antibody-Drug Conjugate Development: A Focus on Roche, Sanofi, BMS, Seagen, and BioNTech

A Comprehensive Approach to Bioconjugate Development

The collaboration between WuXi XDC and Celltrion involves a delegated partnership where WuXi XDC will serve as the primary service provider for integrated projects related to bioconjugate development. This includes various stages from process development to Good Manufacturing Practice (GMP) manufacturing on a global scale. The aim is to leverage WuXi XDC’s expertise to accelerate the development of ADCs, a promising area of biopharmaceuticals.

WuXi XDC is set to play a strategic role as a service partner, supporting Celltrion’s innovative pipeline. The services encompass the entire spectrum, from process development to one-stop GMP manufacturing. This strategic collaboration aims to expedite the development of ADCs, ensuring a rapid and high-quality approach. Celltrion’s Vice President, Mr. Jong Moon Cho, expresses confidence in WuXi XDC’s advanced platform and expertise in ADC development.

Fostering Innovation for Global Healthcare

Celltrion emphasizes its commitment to fostering innovation to address unmet healthcare needs and contribute to the sustainability of healthcare systems. WuXi XDC’s CEO, Dr. Jimmy Li, highlights the excitement of collaborating with Celltrion and reaffirms their dedication to enabling clients to advance innovative therapeutics with speed and quality. The partnership reflects a shared commitment to benefit patients worldwide through cutting-edge bioconjugate solutions.

The partnership between Celltrion and WuXi XDC marks a significant step in advancing bioconjugate solutions, particularly ADCs. By combining Celltrion’s innovative pipeline with WuXi XDC’s global CRDMO capabilities, the collaboration aims to not only accelerate development but also contribute to the well-being of patients worldwide.

Author

Sinead Huang